Dr Guyer is Co-Founder, Chief Executive Officer, and Executive Chairman of the Board of Ophthotech Corporation. Dr Guyer has significant medical, drug development and commercial experience in ophthalmology.
Under Dr Guyer’s leadership, Ophthotech raised more than $350 million in financing in 2013, and in 2014 entered into an ex-US licensing and commercialization deal with Novartis for Fovista® potentially worth over $1 billion (including a $200 million upfront fee), placing the deal as one of the largest ex-US partnering transactions ever in the biotechnology industry.
Dr Guyer obtained his Bachelor of Science degree from Yale College summa cum laude and his medical degree from Johns Hopkins Medical School. He completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital, followed by a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School. Dr Guyer served as Professor and Chairman of the Department of Ophthalmology at New York University (NYU) School of Medicine from 2000-2002.
Dr Guyer co-founded and served as CEO and Director of Eyetech Pharmaceuticals, Inc., where he led the company through private, public and corporate financings over $400 million, until it was acquired by OSI Pharmaceuticals Inc for $935 million in 2005. Prior to joining Ophthotech, Dr Guyer worked as a venture capitalist and Partner at SV Life Sciences, and has served on multiple Boards of both public and private companies.
Dr Guyer has received various awards during his career including the 2003 Ernst & Young Entrepreneur of the Year Award in Life Science, and the Castle Connolly Medical Ltd. Awards for New York Metro Area Top Doctor 2003, New York Magazine Top Doctor 2003, 2004, and America’s Top Doctor 2003, 2004.
Dr Guyer was the Chief Medical Editor of the Ophthalmology Times from 1996-2004. Dr Guyer has authored 3 textbooks, over 25 textbook chapters, and published over 80 articles in peer-reviewed journals. He is a member of several professional societies.